| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.028 | 0.8 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.037 | 0.8 |